SPARQL
Downloads
Documentation/Help
Skip Header
Results
Your Query
Add common prefixes
DESCRIBE <http://purl.uniprot.org/SHA-384/F2FC60B4687879B3EA73DB228EE829AC198AEE951454E39C546CAE121D743E3DDD298503BD06B7294ADF221E5391954A>
Submit Query
Cancel
RDF/XML
NTriples
Turtle
Show query
Share
Subject
Predicate
Object
http://purl.uniprot.org/SHA-384/F2FC60B4687879B3EA73DB228EE829AC198AEE951454E39C546CAE121D743E3DDD298503BD06B7294ADF221E5391954A
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://purl.uniprot.org/core/Annotation
http://purl.uniprot.org/SHA-384/F2FC60B4687879B3EA73DB228EE829AC198AEE951454E39C546CAE121D743E3DDD298503BD06B7294ADF221E5391954A
http://www.w3.org/2000/01/rdf-schema#comment
"Data show that KIR activation and HLA expression density are critical determinants for the efficacy of rituximab treatment."
xsd:string
http://purl.uniprot.org/uniprot/#_A98283F7426869DFC516D373DF962A1D52223DCAECA7C8DB8D9DAB3758E662FDA49FB83EFEF5196149A9FD8CF4853B8E
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
http://purl.uniprot.org/SHA-384/F2FC60B4687879B3EA73DB228EE829AC198AEE951454E39C546CAE121D743E3DDD298503BD06B7294ADF221E5391954A
http://purl.uniprot.org/uniprot/P43626
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/F2FC60B4687879B3EA73DB228EE829AC198AEE951454E39C546CAE121D743E3DDD298503BD06B7294ADF221E5391954A
http://purl.uniprot.org/uniprot/#_P43626-mappedCitation-20056126
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/F2FC60B4687879B3EA73DB228EE829AC198AEE951454E39C546CAE121D743E3DDD298503BD06B7294ADF221E5391954A